Aptinyx Investor Relations Material
Latest events
Q3 2022
Aptinyx
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Aptinyx Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders with unmet medical need. The Company's two clinical programs include APTX101, which is being developed as a monotherapy for adults with refractory or high risk myoclonic seizures and adults with refractory partial onset seizures (ROS), and APTX102, which is being developed as a monotherapy for the treatment of adults with drug-resistant epilepsy (RxR-XII)
Latest articles
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
Ticker symbol
APTX
Country
🇺🇸 United States